Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic CancerBusiness Wire • 03/26/26
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC TreatmentZacks Investment Research • 03/09/26
NovoCure (NVCR) Reliance on International Sales: What Investors Need to KnowZacks Investment Research • 03/02/26
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung CancerBusiness Wire • 03/02/26
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company UpdateBusiness Wire • 02/26/26
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)Business Wire • 02/24/26
Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 02/19/26
Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic CancerZacks Investment Research • 02/17/26
NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity ApproachingSeeking Alpha • 02/12/26
U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic CancerBusiness Wire • 02/11/26
NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company UpdateBusiness Wire • 01/12/26